Syncromune®, a Florida-based biotech specializing in combination immunotherapies, raises $100M in Series A to advance its in situ therapy platform for metastatic solid tumors; Phase 1 trials are underway for its lead candidates, SV-101 and SV-102. https://lnkd.in/e8A-55fk
